Hyperthermia has been defined as the process of increasing the temperature of the body or a particular region of it beyond the threshold level set at a particular moment by the thermoregulatory system of an organism [1]. The stage of the cancer, the locations of malignancies and their depths inside the body, play a role when choosing the appropriate method of clinical hyperthermia application out of the existing three standard options: whole-body, regional, or local hyperthermia. While whole-body heat application is used to treat deep seated and disseminated malignancies, local or regional treatments deliver heat to localized or advanced cancer, respectively [2]. During the last decades, hyperthermia has been only used in combination with radiotherapy or chemotherapy mainly due to operational constraints and the incidence of harmful secondary effects that were found to affect the surrounding healthy tissues [3,4]. Some thermal damage, such as the appearance of burns on external tissue, is a common side effect of treatment. This can be avoided by maximizing toxic effects on the tumor area and confining the heating to the volume of the tumor mass [1]. In addition to thermal damage, transient adverse effects such as vomiting, diarrhea, and nausea may appear. On rare and extreme occasions cardiac, vasculature and cerebral disorders may arise [5,6]. Since these occurrences are highly uncommon, and the ability to control, monitor, and understand hyperthermia and its effects has increased over recent years, its side effects are generally considered to be not serious, especially in comparison to other cancer treatments [5].Several studies testing the clinical benefits of hyperthermia have been performed, providing evidence that hyperthermia is less efficacious when applied as a single therapy, with limiting factors such as the reproducibility of heat deposition into the tumor mass, the formation of hotspots [4,7], and the challenging measurement of the temperature within the tumor and its vicinity.Nevertheless, hyperthermia has been demonstrated in trials to prolong life and decrease disease re-appraisal as an adjuvant therapy, damaging cancer cells and causing radiation and chemosensitization, with some tumors being more responsive than